Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Solid Tumor 1Clear-cell metastatic renal cell carcinoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × LY2510924 × Clear all
NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
9 enrolled 13 charts
Other solid neoplasm

Solid Tumor

NCT01391130 2019-07-23

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Eli Lilly and Company

Phase 2 Terminated
110 enrolled 14 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Neoplasm Metastasis, Neoplasms

NCT01439568 2019-07-23

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Eli Lilly and Company

Phase 2 Completed
90 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡